Starpharma Holdings Ltd. (OTCMKTS:SPHRY – Get Free Report)’s stock price fell 11.5% during mid-day trading on Friday . The stock traded as low as $2.30 and last traded at $2.30. 1,100 shares changed hands during trading, a decline of 40% from the average session volume of 1,833 shares. The stock had previously closed at $2.60.
Starpharma Stock Performance
The company has a debt-to-equity ratio of 0.06, a current ratio of 4.32 and a quick ratio of 3.95. The firm has a 50 day moving average price of $2.50 and a 200 day moving average price of $1.65.
About Starpharma
Starpharma is a clinical-stage biopharmaceutical company specializing in the development of dendrimer-based products across infectious disease, oncology and ophthalmology. Its proprietary dendrimer platform, DEP™ (Dendrimer Enhanced Products), enables precise molecular engineering to enhance drug delivery, targeting and safety profiles. The company’s lead product, VivaGel®, is a topical microbicide that has been approved in multiple markets for the treatment and prevention of bacterial vaginosis and is in clinical development for antiviral applications.
In addition to VivaGel, Starpharma is advancing pipeline candidates that leverage DEP technology to improve the performance of established and novel therapeutic agents.
See Also
- Five stocks we like better than Starpharma
- Do not delete, read immediately
- How a Family Trust May Be Able To Help Preserve Your Wealth
- URGENT: Trump Just Triggered AI’s Biggest Disruption Yet
- Wall Street Alert: Buy AES
- A U.S. “birthright” claim worth trillions – activated quietly
Receive News & Ratings for Starpharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Starpharma and related companies with MarketBeat.com's FREE daily email newsletter.
